Fintel reports that on June 3, 2025, Oppenheimer initiated coverage of Axsome Therapeutics (NasdaqGM:AXSM) with a Outperform ...

Any point can be considered low -- even after massive gains -- provided there is plenty of upside left. That brings us to ...

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In a report dated May 30, Morgan Stanley analyst Vikram Purohit reaffirmed his Buy rating on Axsome Therapeutics Inc. (NASDAQ ...

Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates ...

HC Wainwright reissued their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research report report published on Thursday morning,Benzinga reports. They currently ...

Axsome Therapeutics, Inc. has announced a new $570 million term loan and revolving credit facility with Blackstone Life Sciences and Blackstone Credit & Insurance, which replaces its previous term ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the first ...

All relevant comments and Axsome Therapeutics Inc share chat regarding the AXSM NASDAQ share news are listed here in the AXSM forum. View and contribute to the AXSM share chat. Discuss Axsome ...

In January, Axsome Therapeutics reported preliminary Auvelity net product sales are expected to be approximately $92.6 million and $291.4 million for the fourth quarter and full year of 2024 ...